Sichuan Qian Li Beoka Medical Technology920199.BJValuation Analysis

As of Oct 19, 2026, Sichuan Qian Li Beoka Medical Technology (920199.BJ) trades at a P/E of 193.00x, P/B of 2.86x, P/S of 6.14x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 66th percentile over the trailing 10Y window (vs. 56th percentile over 3Y); P/B sits at the 47th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/S sits at the 54th percentile over the trailing 10Y window (vs. 41st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 94th percentile within its industry and the 91st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 18.7 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Sichuan Qian Li Beoka Medical Technology operates in the — sector. Data refreshes weekly and is for reference only, not investment advice.